Back to Search Start Over

Development and

Authors :
German, Nacher-Soler
Antoine, Marteyn
Natasha, Barenzung
Stéphanie, Sgroi
Karl-Heinz, Krause
Pascal, Senn
Francis, Rousset
Source :
Frontiers in neurology. 13
Publication Year :
2022

Abstract

The reactive oxygen species (ROS)-generating enzyme NOX3 has recently been implicated in the pathophysiology of several acquired forms of sensorineural hearing loss, including cisplatin-, noise- and age-related hearing loss. NOX3 is highly and specifically expressed in the inner ear and therefore represents an attractive target for specific intervention aiming at otoprotection. Despite the strong rationale to inhibit NOX3, there is currently no specific pharmacological inhibitor available. Molecular therapy may represent a powerful alternative. In this study, we developed and tested a collection of small interfering (si) RNA constructs to establish a proof of concept of NOX3 inhibition through local delivery in the mouse inner ear. The inhibitory potential of 10 different siRNA constructs was first assessed in three different cells lines expressing the NOX3 complex. Efficacy of the most promising siRNA construct to knock-down NOX3 was then further assessed

Details

ISSN :
16642295
Volume :
13
Database :
OpenAIRE
Journal :
Frontiers in neurology
Accession number :
edsair.pmid..........6c71aea419f1d9689440bac252bfc10c